High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation
Status:
Unknown status
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
This randomized, open-label study is aimed to evaluate the efficacy of high-dose icotinib in
treating advanced non-small cell lung cancer patients with positive EGFR 21 exon mutation.